Trial Profile

Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Oct 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofranergene obadenovec (Primary)
Indications Thyroid cancer
Focus Proof of concept; Therapeutic Use
Sponsors VBL Therapeutics

Most Recent Events

14 Aug 2017 According to a VBL Therapeutics media release,the company provided an update on long-term survival from this trial at the BIO International Convention.
19 Jun 2017 According to a VBL Therapeutics media release, long-term survival data from this trial will be presented at 2017 BIO International Convention.
19 Jun 2017 Long-term survival data from this trial published in a VBL Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com